Clinical Laserthermia Systems

"During his time as CFO, Rolf has played an essential role in CLS' market establishment and commercialization of our laser ablation products in the US, Europe, and Asia-Pacific region as well as for our growth strategy with the ambition to reach break-even by the end of 2025. Not least, his efforts to secure the company's financing have been decisive. I thank Rolf for good collaboration and wish him the best of luck in the future," says Dan J. Mogren, CEO, CLS.

The information was submitted for publication, through the agency of the contact person set out below on 8 September 2023, at CEST 18:30.

Contact Information:


Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 - (0)705 - 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: www.clinicallaser.se